$RCEL
AVITA Medical, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024093964 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $19.55M $15.20M
YoY Change 43.25% 29.29%
Cost Of Revenue $3.190M $2.111M
YoY Change 50.97% -4.22%
Gross Profit $16.36M $13.08M
YoY Change 41.83% 37.02%
Gross Profit Margin 83.68% 86.11%
Selling, General & Admin $24.73M $23.82M
YoY Change 48.5% 47.33%
% of Gross Profit 151.22% 182.06%
Research & Development $5.428M $4.887M
YoY Change 23.53% -3.72%
% of Gross Profit 33.19% 37.35%
Depreciation & Amortization $288.0K $187.0K
YoY Change 84.62% 36.5%
% of Gross Profit 1.76% 1.43%
Operating Expenses $30.16M $28.71M
YoY Change 43.29% 35.13%
Operating Profit -$13.81M -$15.62M
YoY Change 48.36% 39.94%
Interest Expense $1.359M $1.347M
YoY Change 13490.0% 19142.86%
% of Operating Profit
Other Income/Expense, Net -$1.068M $1.611M
YoY Change -272.26% 101.12%
Pretax Income -$16.23M -$15.36M
YoY Change 86.56% 48.11%
Income Tax -$28.00K $33.00K
% Of Pretax Income
Net Earnings -$16.21M -$15.39M
YoY Change 86.01% 48.24%
Net Earnings / Revenue -82.91% -101.3%
Basic Earnings Per Share -$0.62 -$0.60
Diluted Earnings Per Share -$0.62 -$0.60
COMMON SHARES
Basic Shares Outstanding 25.99M 25.80M
Diluted Shares Outstanding 25.98M 25.76M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.41M $54.06M
YoY Change -26.14% -18.16%
Cash & Equivalents $18.64M $17.45M
Short-Term Investments $25.77M $36.60M
Other Short-Term Assets $2.892M $8.000K
YoY Change 11023.08% -98.48%
Inventory $6.229M $6.709M
Prepaid Expenses $2.159M
Receivables $10.29M $8.717M
Other Receivables $111.0K $94.00K
Total Short-Term Assets $63.93M $72.96M
YoY Change -13.53% -5.85%
LONG-TERM ASSETS
Property, Plant & Equipment $9.151M $7.024M
YoY Change 391.46% 339.55%
Goodwill
YoY Change
Intangibles $590.0K $545.0K
YoY Change 28.54% 19.52%
Long-Term Investments
YoY Change
Other Assets $546.0K $473.0K
YoY Change 131.36% 65.96%
Total Long-Term Assets $17.13M $14.87M
YoY Change 141.65% 68.29%
TOTAL ASSETS
Total Short-Term Assets $63.93M $72.96M
Total Long-Term Assets $17.13M $14.87M
Total Assets $81.05M $87.83M
YoY Change 0.05% 1.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.187M $4.155M
YoY Change 39.57% 8.29%
Accrued Expenses $9.776M $8.444M
YoY Change 22.2% 23.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.14M $13.79M
YoY Change 44.82% -0.17%
LONG-TERM LIABILITIES
Long-Term Debt $42.55M $40.99M
YoY Change
Other Long-Term Liabilities $9.136M $9.135M
YoY Change 47.35% 135.86%
Total Long-Term Liabilities $42.55M $40.99M
YoY Change 586.24% 958.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.14M $13.79M
Total Long-Term Liabilities $42.55M $40.99M
Total Liabilities $68.60M $63.51M
YoY Change 294.09% 285.98%
SHAREHOLDERS EQUITY
Retained Earnings -$348.2M -$332.0M
YoY Change 19.7% 17.66%
Common Stock $3.000K $3.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.23M $23.92M
YoY Change
Total Liabilities & Shareholders Equity $81.05M $87.83M
YoY Change 0.05% 1.73%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$16.21M -$15.39M
YoY Change 86.01% 48.24%
Depreciation, Depletion And Amortization $288.0K $187.0K
YoY Change 84.62% 36.5%
Cash From Operating Activities -$7.214M -$12.78M
YoY Change -19.67% 40.42%
INVESTING ACTIVITIES
Capital Expenditures $3.760M $2.652M
YoY Change 637.25% 786.96%
Acquisitions
YoY Change
Other Investing Activities $11.15M $15.08M
YoY Change -49.91% -19.17%
Cash From Investing Activities $7.394M $12.43M
YoY Change -66.02% -32.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.007M 849.0K
YoY Change 67.83% 396.49%
NET CHANGE
Cash From Operating Activities -7.214M -12.78M
Cash From Investing Activities 7.394M 12.43M
Cash From Financing Activities 1.007M 849.0K
Net Change In Cash 1.187M 501.0K
YoY Change -91.13% -94.69%
FREE CASH FLOW
Cash From Operating Activities -$7.214M -$12.78M
Capital Expenditures $3.760M $2.652M
Free Cash Flow -$10.97M -$15.43M
YoY Change 15.64% 64.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001762303
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://avitamedical.com/20240630#ContractualMaturitiesMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://avitamedical.com/20240630#ContractualMaturitiesMember
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2024Q2 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense
us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense
CY2023Q2 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense
us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39059
dei Entity Registrant Name
EntityRegistrantName
AVITA MEDICAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1021707
dei Entity Address Address Line1
EntityAddressAddressLine1
28159 Avenue Stanford
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 220
dei Entity Address City Or Town
EntityAddressCityOrTown
Valencia
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91355
dei City Area Code
CityAreaCode
(661)
dei Local Phone Number
LocalPhoneNumber
367-9170
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
RCEL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25989699
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17452000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22118000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
36604000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
66939000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8717000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7664000
CY2024Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
94000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
30000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3382000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1659000
CY2024Q2 us-gaap Fifo Inventory Amount
FIFOInventoryAmount
6709000
CY2023Q4 us-gaap Fifo Inventory Amount
FIFOInventoryAmount
5596000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
72958000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
104006000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7024000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1877000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3938000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2440000
CY2024Q2 rcel Corporate Owned Life Insurance Asset
CorporateOwnedLifeInsuranceAsset
2888000
CY2023Q4 rcel Corporate Owned Life Insurance Asset
CorporateOwnedLifeInsuranceAsset
2475000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
545000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
487000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
473000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
355000
CY2024Q2 us-gaap Assets
Assets
87826000
CY2023Q4 us-gaap Assets
Assets
111640000
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4155000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3793000
CY2024Q2 rcel Accrued Wages And Fringe Benefits
AccruedWagesAndFringeBenefits
7624000
CY2023Q4 rcel Accrued Wages And Fringe Benefits
AccruedWagesAndFringeBenefits
7972000
CY2024Q2 rcel Non Qualified Deferred Compensation Plan Liability Current
NonQualifiedDeferredCompensationPlanLiabilityCurrent
753000
CY2023Q4 rcel Non Qualified Deferred Compensation Plan Liability Current
NonQualifiedDeferredCompensationPlanLiabilityCurrent
168000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1255000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1266000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13787000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13199000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40989000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
39812000
CY2024Q2 rcel Non Qualified Deferred Compensation Plan Liability
NonQualifiedDeferredCompensationPlanLiability
3148000
CY2023Q4 rcel Non Qualified Deferred Compensation Plan Liability
NonQualifiedDeferredCompensationPlanLiability
3663000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
340000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
357000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3281000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1702000
CY2024Q2 rcel Warrant Liability
WarrantLiability
1968000
CY2023Q4 rcel Warrant Liability
WarrantLiability
3158000
CY2024Q2 us-gaap Liabilities
Liabilities
63513000
CY2023Q4 us-gaap Liabilities
Liabilities
61891000
CY2024Q2 rcel Non Qualified Deferred Compensation Plan Share Awards
NonQualifiedDeferredCompensationPlanShareAwards
398000
CY2023Q4 rcel Non Qualified Deferred Compensation Plan Share Awards
NonQualifiedDeferredCompensationPlanShareAwards
693000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25949906
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25949906
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25682078
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25682078
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 rcel Common Stock Held By Non Qualified Deferred Compensation Plan
CommonStockHeldByNonQualifiedDeferredCompensationPlan
-1022000
CY2023Q4 rcel Common Stock Held By Non Qualified Deferred Compensation Plan
CommonStockHeldByNonQualifiedDeferredCompensationPlan
-1130000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
358510000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
350039000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1556000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1887000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-332020000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-297969000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
23915000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
49056000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87826000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
111640000
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15183000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11753000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
26287000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
22303000
CY2024Q2 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
12000
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
12000
CY2024Q2 us-gaap Revenues
Revenues
15195000
CY2023Q2 us-gaap Revenues
Revenues
11753000
us-gaap Revenues
Revenues
26299000
us-gaap Revenues
Revenues
22303000
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
2111000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
2204000
us-gaap Cost Of Revenue
CostOfRevenue
3624000
us-gaap Cost Of Revenue
CostOfRevenue
3871000
CY2024Q2 us-gaap Gross Profit
GrossProfit
13084000
CY2023Q2 us-gaap Gross Profit
GrossProfit
9549000
us-gaap Gross Profit
GrossProfit
22675000
us-gaap Gross Profit
GrossProfit
18432000
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
530000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1157000
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16302000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10003000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28942000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16543000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7519000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6165000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16481000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14460000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4887000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5076000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10081000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9662000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
28708000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
21244000
us-gaap Operating Expenses
OperatingExpenses
55504000
us-gaap Operating Expenses
OperatingExpenses
40665000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15624000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11165000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32829000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21076000
CY2024Q2 us-gaap Interest Expense
InterestExpense
1347000
CY2023Q2 us-gaap Interest Expense
InterestExpense
7000
us-gaap Interest Expense
InterestExpense
2703000
us-gaap Interest Expense
InterestExpense
11000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1611000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
801000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1544000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1526000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15360000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10371000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33988000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19561000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
33000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
43000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-15393000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-10384000
us-gaap Net Income Loss
NetIncomeLoss
-34051000
us-gaap Net Income Loss
NetIncomeLoss
-19604000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.6
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.6
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25760278
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25760278
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25239723
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25239723
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25699030
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25699030
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25221009
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25221009
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-15393000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-10384000
us-gaap Net Income Loss
NetIncomeLoss
-34051000
us-gaap Net Income Loss
NetIncomeLoss
-19604000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-10000
CY2024Q2 rcel Gain Loss On Change In Fair Value Due To Credit Risk On Long Term Debt
GainLossOnChangeInFairValueDueToCreditRiskOnLongTermDebt
1530000
rcel Gain Loss On Change In Fair Value Due To Credit Risk On Long Term Debt
GainLossOnChangeInFairValueDueToCreditRiskOnLongTermDebt
438000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
100000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-107000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
342000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13881000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10283000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33720000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19272000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
32569000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-15393000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3978000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
63000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
786000
CY2024Q2 rcel Change In Redemption Value Of Share Awards In Nqdc Plan
ChangeInRedemptionValueOfShareAwardsInNQDCPlan
400000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
CY2024Q2 rcel Change In Fair Value Due To Credit Risk On Long Term Debt
ChangeInFairValueDueToCreditRiskOnLongTermDebt
1530000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
23915000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
77561000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-10384000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1175000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
661000
CY2023Q2 rcel Change In Redemption Value Of Share Awards In Nqdc Plan
ChangeInRedemptionValueOfShareAwardsInNQDCPlan
-467000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
100000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
68647000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
49056000
us-gaap Net Income Loss
NetIncomeLoss
-34051000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6563000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
694000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
786000
rcel Distribution Diversification Of Common Stock Held By The Nqdc Plan
DistributionDiversificationOfCommonStockHeldByTheNqdcPlan
264000
rcel Change In Redemption Value Of Share Awards In Nqdc Plan
ChangeInRedemptionValueOfShareAwardsInNQDCPlan
272000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-107000
rcel Change In Fair Value Due To Credit Risk On Long Term Debt
ChangeInFairValueDueToCreditRiskOnLongTermDebt
438000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
23915000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84740000
us-gaap Net Income Loss
NetIncomeLoss
-19604000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3372000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
832000
rcel Change In Redemption Value Of Share Awards In Nqdc Plan
ChangeInRedemptionValueOfShareAwardsInNQDCPlan
-1025000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-10000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
342000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
68647000
us-gaap Net Income Loss
NetIncomeLoss
-34051000
us-gaap Net Income Loss
NetIncomeLoss
-19604000
rcel Change In Fair Value Of Long Term Debt
ChangeInFairValueOfLongTermDebt
1615000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1190000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
407000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
281000
us-gaap Share Based Compensation
ShareBasedCompensation
6618000
us-gaap Share Based Compensation
ShareBasedCompensation
3783000
rcel Non Cash Lease Expense
NonCashLeaseExpense
427000
rcel Non Cash Lease Expense
NonCashLeaseExpense
331000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-5000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
16000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
4000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-12000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4000
rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-234000
rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-68000
rcel Estimated Deferred Costs
EstimatedDeferredCosts
-64000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
170000
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
91000
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
202000
rcel Amortization Of Premium Of Marketable Securities
AmortizationOfPremiumOfMarketableSecurities
-1152000
rcel Amortization Of Premium Of Marketable Securities
AmortizationOfPremiumOfMarketableSecurities
-621000
rcel Non Cash Changes In Fair Value Of Non Qualified Deferred Compensation Plan
NonCashChangesInFairValueOfNonQualifiedDeferredCompensationPlan
380000
rcel Non Cash Changes In Fair Value Of Non Qualified Deferred Compensation Plan
NonCashChangesInFairValueOfNonQualifiedDeferredCompensationPlan
-937000
rcel Increase Decrease In Trade And Other Receivables
IncreaseDecreaseInTradeAndOtherReceivables
-1144000
rcel Increase Decrease In Trade And Other Receivables
IncreaseDecreaseInTradeAndOtherReceivables
-2440000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
63000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-456000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1723000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
295000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1347000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1003000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-447000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-344000
rcel Increase Decrease In Corporate Owned Life Insurance Asset
IncreaseDecreaseInCorporateOwnedLifeInsuranceAsset
215000
rcel Increase Decrease In Corporate Owned Life Insurance Asset
IncreaseDecreaseInCorporateOwnedLifeInsuranceAsset
681000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
118000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
164000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1402000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
747000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-348000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-422000
rcel Increase Decrease In Current Non Qualified Deferred Compensation Liability
IncreaseDecreaseInCurrentNonQualifiedDeferredCompensationLiability
755000
rcel Increase Decrease In Current Non Qualified Deferred Compensation Liability
IncreaseDecreaseInCurrentNonQualifiedDeferredCompensationLiability
794000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
91000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
229000
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-318000
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-221000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-17000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-324000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33644000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18174000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5819000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7633000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
37200000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
45388000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3799000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
583000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
84000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
22000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27498000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37150000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
694000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
342000
rcel Employee Stock Purchase Plan Espp Purchases
EmployeeStockPurchasePlanEsppPurchases
786000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1480000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
342000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4666000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19321000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22118000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18164000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17452000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37485000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
19000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
44000
us-gaap Interest Paid Net
InterestPaidNet
2703000
us-gaap Interest Paid Net
InterestPaidNet
11000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
342000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
115000
rcel Right Of Use Asset Obtained In Exchange For Lease Liabilities
RightOfUseAssetObtainedInExchangeForLeaseLiabilities
2026000
rcel Exercise Of Stock Options Not Yet Paid
ExerciseOfStockOptionsNotYetPaid
490000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the accompanying Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts (including estimate of the average selling price for PermeaDerm sales, stand-alone selling price ("SSP") for the RPD, allowance for credit losses, reserves for inventory excess and obsolescence, carrying value of long-lived assets, the useful lives of long-lived assets, accounting for marketable securities, income taxes, fair value of debt, fair value of warrants and stock-based compensation) and related disclosures. Estimates have been prepared based on the current and available information. However, actual results could differ from estimated amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
-7000
us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
-12000
CY2024Q2 rcel Cash At Deposit Institutions
CashAtDepositInstitutions
6600000
CY2023Q4 rcel Cash At Deposit Institutions
CashAtDepositInstitutions
10700000
CY2024Q2 rcel Cash In Foreign Institutions
CashInForeignInstitutions
0
CY2023Q4 rcel Cash In Foreign Institutions
CashInForeignInstitutions
69000
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10800000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
11400000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables and debt and other liabilities. As of June 30, 2024 and December 31, 2023, substantially all the Company’s cash was deposited in accounts at financial institutions, and amounts exceed federally insured limits and are subject to the risk of bank failure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> single commercial customer accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of net accounts receivable or more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenues for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-months and six-months ended June 30, 2024 and 2023.</span></p>
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
36615000
CY2024Q2 rcel Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
11000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
36604000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
66844000
CY2023Q4 rcel Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
100000
CY2023Q4 rcel Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
5000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
66939000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
36615000
CY2024Q2 rcel Available For Sale Securities Debt Maturities Within One Year Carrying Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearCarryingValue
36604000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
66844000
CY2023Q4 rcel Available For Sale Securities Debt Maturities Within One Year Carrying Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearCarryingValue
66939000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-11000
CY2023 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
95000
CY2024Q2 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
CY2023Q2 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q2 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
12000
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
12000
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
545000
CY2023Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
390000
CY2024Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2024Q2 rcel Debt Instrument Outstanding Amount Addition Reduction To Liability
DebtInstrumentOutstandingAmountAdditionReductionToLiability
989000
CY2023Q4 rcel Debt Instrument Outstanding Amount Addition Reduction To Liability
DebtInstrumentOutstandingAmountAdditionReductionToLiability
-188000
CY2024Q2 rcel Increase In Operating Lease Rou Assets And Operating Lease Liabilities
IncreaseInOperatingLeaseRouAssetsAndOperatingLeaseLiabilities
2100000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
298000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
197000
us-gaap Operating Lease Cost
OperatingLeaseCost
594000
us-gaap Operating Lease Cost
OperatingLeaseCost
395000
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
36000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
13000
us-gaap Variable Lease Cost
VariableLeaseCost
71000
us-gaap Variable Lease Cost
VariableLeaseCost
26000
CY2024Q2 us-gaap Lease Cost
LeaseCost
334000
CY2023Q2 us-gaap Lease Cost
LeaseCost
210000
us-gaap Lease Cost
LeaseCost
665000
us-gaap Lease Cost
LeaseCost
421000
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
293000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
205000
us-gaap Operating Lease Payments
OperatingLeasePayments
587000
us-gaap Operating Lease Payments
OperatingLeasePayments
410000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3938000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2440000
CY2024Q2 rcel Right Of Use Assets
RightOfUseAssets
3938000
CY2023Q4 rcel Right Of Use Assets
RightOfUseAssets
2440000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
820000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
895000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3281000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1702000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4101000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2597000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M7D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M21D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0969
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0875
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
598000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1165000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1125000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
773000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
658000
CY2024Q2 rcel Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
853000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5172000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1071000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4101000
CY2024Q2 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
12000
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
12000
CY2024Q2 us-gaap Property Subject To Or Available For Operating Lease Gross
PropertySubjectToOrAvailableForOperatingLeaseGross
222000
CY2024Q2 us-gaap Property Subject To Or Available For Operating Lease Accumulated Depreciation
PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation
2000
CY2024Q2 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
220000
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2760000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3683000
CY2024Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
433000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
878000
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3516000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1035000
CY2024Q2 us-gaap Inventory Net
InventoryNet
6709000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5596000
CY2024Q2 rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-151000
CY2023Q2 rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-2000
rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-234000
rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-68000
CY2024Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
685000
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
140000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
545000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
616000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
129000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
487000
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
34000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
37000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
73000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
52000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
38000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
38000
CY2024Q2 rcel Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
253000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
491000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2773000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2432000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7024000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1877000
rcel Operating Lease Assets Maximum Number Of Uses
OperatingLeaseAssetsMaximumNumberOfUses
200
CY2024Q2 us-gaap Depreciation
Depreciation
187000
CY2023Q2 us-gaap Depreciation
Depreciation
137000
us-gaap Depreciation
Depreciation
373000
us-gaap Depreciation
Depreciation
264000
CY2024Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
5000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
5000
CY2023Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
3000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
3000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2159000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1376000
CY2024Q2 rcel Amounts Due From Stedical
AmountsDueFromStedical
979000
CY2024Q2 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
212000
CY2023Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
227000
CY2024Q2 rcel Lease Deposits Current
LeaseDepositsCurrent
24000
CY2023Q4 rcel Lease Deposits Current
LeaseDepositsCurrent
38000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
8000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
18000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3382000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1659000
CY2024Q2 us-gaap Deposit Assets
DepositAssets
175000
CY2023Q4 us-gaap Deposit Assets
DepositAssets
155000
CY2024Q2 rcel Other Long Term Assets Long Term Prepaids
OtherLongTermAssetsLongTermPrepaids
119000
CY2023Q4 rcel Other Long Term Assets Long Term Prepaids
OtherLongTermAssetsLongTermPrepaids
148000
CY2024Q2 rcel Other Long Term Assets Non Current
OtherLongTermAssetsNonCurrent
179000
CY2023Q4 rcel Other Long Term Assets Non Current
OtherLongTermAssetsNonCurrent
52000
CY2024Q2 rcel Other Long Term Assets
OtherLongTermAssets
473000
CY2023Q4 rcel Other Long Term Assets
OtherLongTermAssets
355000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
820000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
895000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
205000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33000
CY2024Q2 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
230000
CY2023Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
338000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1255000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1266000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q2 us-gaap Revenues
Revenues
15195000
CY2023Q2 us-gaap Revenues
Revenues
11753000
us-gaap Revenues
Revenues
26299000
us-gaap Revenues
Revenues
22303000
CY2024Q2 us-gaap Revenues
Revenues
15195000
CY2023Q2 us-gaap Revenues
Revenues
11753000
us-gaap Revenues
Revenues
26299000
us-gaap Revenues
Revenues
22303000
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
2111000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
2204000
us-gaap Cost Of Revenue
CostOfRevenue
3624000
us-gaap Cost Of Revenue
CostOfRevenue
3871000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25949906
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25949906
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25682078
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25682078
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2023Q2 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4027000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1143000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6618000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3783000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2690158
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1549158
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
117657
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
112880
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
165750
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3843029
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1373860
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3843029
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
235132
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
55200
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
53918
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
22104
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
214310
CY2023Q2 rcel Employee Stock Purchases Plan Effective Date
EmployeeStockPurchasesPlanEffectiveDate
2023-07-01
CY2023Q2 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
1000000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
33000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
43000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-15393000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-10384000
us-gaap Net Income Loss
NetIncomeLoss
-34051000
us-gaap Net Income Loss
NetIncomeLoss
-19604000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25760000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25760000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25240000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25240000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25699000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25699000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25221000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25221000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.6
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.6
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
93845
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2024Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
518000
CY2023Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
249000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1400000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
671000
CY2024Q2 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
3900000
CY2023Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
3800000
CY2024Q2 rcel Payout Of Deferred Compensation Liability
PayoutOfDeferredCompensationLiability
0
rcel Payout Of Deferred Compensation Liability
PayoutOfDeferredCompensationLiability
215000
rcel Payout Of Deferred Compensation Liability
PayoutOfDeferredCompensationLiability
82000
us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
101526
CY2023 us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
81052
rcel Deferred Compensation Arrangement With Individual Shares Vested
DeferredCompensationArrangementWithIndividualSharesVested
93845
CY2023 rcel Deferred Compensation Arrangement With Individual Shares Vested
DeferredCompensationArrangementWithIndividualSharesVested
99106
rcel Deferred Compensation Arrangement With Individual Vested Redemption Value
DeferredCompensationArrangementWithIndividualVestedRedemptionValue
1000000
CY2023 rcel Deferred Compensation Arrangement With Individual Vested Redemption Value
DeferredCompensationArrangementWithIndividualVestedRedemptionValue
1100000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-093964-index-headers.html Edgar Link pending
0000950170-24-093964-index.html Edgar Link pending
0000950170-24-093964.txt Edgar Link pending
0000950170-24-093964-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img179647352_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R9.htm Edgar Link pending
rcel-20240630.htm Edgar Link pending
rcel-20240630.xsd Edgar Link pending
rcel-ex31_1.htm Edgar Link pending
rcel-ex31_2.htm Edgar Link pending
rcel-ex32.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
rcel-20240630_htm.xml Edgar Link completed